成大醫院血液科臨床試驗

R/R acute leukemia (P1) or R/R AML per WHO 2022 (P2); molecularly selected (KMT2Ar or NPM1m); ECOG 0–2 (or adolescent PS ≥70)

Adult RRMM with measurable disease; prior PI + IMiD + anti-CD38; ECOG 0–1; adequate renal/hepatic/hematologic function;

Adults >=18 with confirmed CLL/SLL, prior covalent BTKi exposure, indication for treatment per iwCLL, ECOG 0–2, protocol-defined organ/marrow function, reproductive safeguards, and life expectancy >6 months.

MM with measurable disease, ECOG ≤2, and 1–3 prior lines (including lenalidomide and a PI) with at least a minimal response to one past treatment. Adequate cardiac, renal, hepatic, and hematologic functions are required, along with signed informed co...

Adults with documented measurable RRMM, prior response (PR+) and progression after last line, 1-3 prior lines, ECOG 0-2, protocol-defined organ/blood function, contraception/pregnancy requirements, informed consent.

Adults (generally 18–80; >80 in approved cohorts), biopsy-proven CD19+ measurable B-NHL (DLBCL/FL), ECOG <=2, adequate marrow/renal/hepatic function, prior therapy requirements per RR vs 1L FL cohorts.

CD19+ R/R B-ALL (Ph+/Ph−), age ≥12 (weight rules if <16), ≥2 prior lines or 1 prior line with no suitable standard option, ECOG ≤2/Lansky ≥50, adequate hepatic/renal/cardiac function, prior therapy washout met, contraception/pregnancy rules met.

Adults >=18 with LGLL or eligible cytotoxic lymphoma, ECOG and disease-specific prior-therapy requirements, adequate organ/coagulation function, and reproductive precautions; disease must be evaluable per protocol response frameworks.

R/R AML/ALL (± MLLr or NPM1m) with required disease/genomic confirmation; age >=18 (site exceptions), ECOG <=2, WBC below protocol threshold, adequate renal/hepatic function, life expectancy >=3 months, contraception/pregnancy requirements met.

Adults (>=18) with histologically confirmed r/r PTCL subtype, ECOG 0–2, prior systemic therapy failure/intolerance (with subtype-specific prior-therapy requirements), transplant-ineligible

after ASCT with NDMM

very low-, low-, intermediate risk MDS, Transfusion dependence assess in 16wks(1U/8weeks), EPO>200, <500.

Adults with PMF/post-PV MF/post-ET MF, ECOG 0–2, TP53WT at randomization, ruxolitinib run-in response in suboptimal range, stable ruxolitinib dosing, protocol-defined hematologic/hepatic/renal function, and strict contraception requirements.

Adults ≥18 with untreated CD20+ classic FL, Ann-Arbor III/IV or II bulky, GELF treatment need, PET+ and measurable lesion(s), ECOG 0-2, adequate organ function, contraception and consent/compliance criteria met.

DLBCL (de novo or histologically transformed from follicular lymphoma or nodal marginal zone lymphoma) with histologically confirmed CD20+ disease, inclusive of the Following the WHO 2016 classification and documented in pathology report: a.DLB...

Adults (≥18) with untreated, active CLL/SLL needing therapy (iwCLL features), measurable burden, ECOG 0–2, oral intake ability, required central del(17p)/TP53 testing, adequate organ function; controlled HBV/HCV/HIV allowed per protocol.

untreat

Adult (>=18) R/R FL1-3a or MZL after >=1 prior systemic line incl anti-CD20; measurable disease; ECOG 0-2; adequate marrow/organ function; informed consent; questionnaire/visit compliance; lenalidomide precautions.

Untreat or Eculizumab stop over 3 m or Ravulizumab stop over 6 m

Adults (>=18) with relapsed/refractory AML after multiple therapies, molecularly confirmed FLT3 or specified spliceosome mutations (SF3B1/SRSF2/U2AF1/ZRSR2), ECOG <=2, adequate hepatic/renal function